Navigation Links
China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
Date:9/10/2007

HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (OTC Bulletin Board: CSKI), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that it won the bidding process organized by the Chinese Ministry of Science and Technology for a $1.5 million grant to further develop its six Early-Stage Cancer Diagnostic Kit project. These six products were created by First Bio-Engineering Company Limited ("First"), the Company's wholly-owned subsidiary. These products will enter into clinical trials in the first half of 2008.

The Company will receive a total grant of $1.5 million over two years, 60% of which will be received in September 2007 and 40% of which will be received in the beginning of 2008. The grant will support the Company's research and development efforts on the six products. The Company will commence the clinical trial in the first half of 2008 to test sensitivity, specificity and accuracy of the products.

The six new products, upon commercial launch, will be used for the fast screening and supplementary clinical diagnosis for various cancers, including the Colloidal Gold Rapid Diagnosis Reagent Kit for each of lung, stomach, intestinal, liver, pancreatic and ovarian cancers.

The bidding process, initiated by the Ministry of Science and Technology of People's Republic of China ("MOST") in early 2007, is to advance the Country's competitiveness in developing world-standard technologies by providing project funding to the winning enterprises. This bidding process, only open to domestic enterprises, consists of multiple stages of assessment and elimination of projects at the provincial as well as the national level. Selection criteria are based on innovation and feasibility of the project.

Mr. Yanqing Liu, Chief Executive Officer and President of China Sky One Medical stated, "This project aims to develop cancer diagnosis techniques and pr
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. How do you level the playing field with China?
2. Medical College receives $377K to study brain disease
3. Barriers will not stop convergence of medical technologies
4. Medical College team creates website for tracking flu
5. Biomedical engineering conference invites manufacturers
6. Visions: Wade offers straight talk on e-medical records
7. Merge unveils updated medical imaging software
8. Medical College receives $1.4M cancer grant
9. Medical technology firm lands $100K federal grant
10. Doyle outlines spending for Medical College, UWM
11. And the winners in medical design are

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ ...ator in biotechnology for diabetes therapy, and a ...rvices to food, supplement, biotechnology and phar...of Tuesday,s Annual Meeting of Shareholders. ,,...ted (Nasdaq: SPEX ) elected the following members...
(Date:11/19/2009)... World,s Top Gene Synthesis Comp... (IGSC) to Coordinate Best Practices in Risk Reduc... of Worldwide Gene Synthesis Capacity , ...f the world’s leading gene synthesis compani...a common screening protocol to promote biosecurity...
(Date:11/18/2009)...ecurity personnel need to be able to find explosiv...ith them. To aid such searches, the National Insti...ort from the Department of Homeland Security, has ...dard Reference Material (SRM) 2905, Trace Particul...ry assay methods, the SRM will be helpful in calib...
(Date:11/18/2009)..., IRVINE, Calif., Nov. 18 /PRNewswire-FirstCall/...se CO-Oximetry(TM) and Measure-Through Motion and ... Lyon, France-based Uni.H.A., one of the largest h...France, has signed a multi-year purchasing agreeme...imeters. The agreement offers preferred contract ...
Breaking Biology Technology:Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4New NIST trace explosives standard slated for homeland security duty 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4
...e-FirstCall/ - Oncothyreon Inc. (NASDAQ:,ONTY) (TS...zation plan to,focus the Company,s resources on th... process development and manufacturing of Stimuvax...linical development of PX-12,beyond the ongoing tr...ntrate Oncothyreon,s efforts and available resourc...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced t...nt in a Phase 1 trial of CVT-3619, a novel oral co...diseases. The U.S. Food and Drug,Administration re...drug,application for CVT-3619, a partial A1 adenos...sess the safety and pharmacokinetic profile,of CVT...
...alidity of Purdue patents; Purdue licenses ...hs, STAMFORD, Conn., Sept. 2 Purdue Pharma L.P. ...Hazelwood, Missouri have,agreed to end the OxyCont...atent infringement lawsuit between them in the Uni...t of New York., According to the agreement, Malli...
Other Biology Technology:Oncothyreon announces prioritization plan for development programs 2Oncothyreon announces prioritization plan for development programs 3Oncothyreon announces prioritization plan for development programs 4Oncothyreon announces prioritization plan for development programs 5CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 2CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2
(Date:11/20/2009)...s are at work on many scientific and technological...cently provided support that totals nearly $4.3 mi...estigators under the American Recovery and Reinves...n awarded grants for investigation of solar phenom...hysics, will enhance the capabilities of NJIT,s Bi...
(Date:11/20/2009)...nvited to contribute their abstracts to the World ...the largest global meeting devoted to all aspects ...tient care. The Congress will be held in Florence,...stracts can be submitted online at http://www.iof...ebruary 4, 2010. , IOF and ESCEO are pleased to ...
(Date:11/20/2009)...tion of a single bacterial gene into yeast, resear...etherlands achieved three improvements in bioethan...ore ethanol, less acetate and elimination of the m...was published in the scientific journal Applied a... Bioethanol is made by the yeast Saccharomyces cer...
Breaking Biology News(10 mins):NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Delft breakthrough in bioethanol production from agricultural waste 2Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 1Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 2Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 1Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 2Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 3Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 4Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 5Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 6Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 1Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 2Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 3
...ls that react with seawater to produce an electric...s develop a strategy to reduce the bycatch of shar...ng priority worldwide given diminished populations... with target species for baited lines, reducing fi... A recent study by NOAA scientists and colleagues...
...2001 the Talibans destroyed two ancient colossal B...ind those statues, there are caves decorated with ...e caves also suffered from Taliban destruction, as...day they have become the source of a major discove...performed at the European Synchrotron Radiation Fa...
...re what we eat, may be the latest recipe for succe...limate warming. Despite the recent popular attent... plate, aka food miles, Carnegie Mellon researcher... in an upcoming article in the prestigious Environ...tary choice, not food miles, which most determines...
Other Biology News:Can certain metals repel sharks from fishing gear? 2Can certain metals repel sharks from fishing gear? 3Synchrotron light unveils oil in ancient Buddhist paintings from Bamiyan 2Carnegie Mellon studies how climate change impacts food production 2
Caveolin Sampler Kit from BD Biosciences Pharmingen
UCB Eosinophil Chip-IHC from 3H Biomedical AB
UCB MSC Cell Chip-IHC from 3H Biomedical AB
B Cell Chip-IHC from 3H Biomedical AB
Biology Products: